{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:46:51Z","timestamp":1792025211955,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"DOI":"10.1007\/s40264-026-01737-8","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:08:21Z","timestamp":1792022901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reassessing the Neoplasm Signal with Fezolinetant: Regulatory Inference, Mechanistic Plausibility, and the Case for Proactive Pharmacovigilance"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7782-9891","authenticated-orcid":false,"given":"Glen","family":"Clack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Renwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"1737_CR1","unstructured":"National Institute for Health and Care Excellence. Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause. Technology appraisal guidance TA1143. London: NICE; 31 March 2026. Sections 3.3 and 3.9."},{"issue":"10413","key":"1737_CR2","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(23)01634-3","volume":"402","author":"J Douxfils","year":"2023","unstructured":"Douxfils J, Beaudart C, Dogn\u00e9 JM. Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant. Lancet. 2023;402(10413):1623\u20135.","journal-title":"Lancet"},{"issue":"6","key":"1737_CR3","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvag082","volume":"10","author":"E Boretti","year":"2026","unstructured":"Boretti E, Dogn\u00e9 JM, Douxfils J. Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications. J Endocr Soc. 2026;10(6):bvag082.","journal-title":"J Endocr Soc"},{"issue":"2","key":"1737_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s12325-024-03073-8","volume":"42","author":"R Kagan","year":"2025","unstructured":"Kagan R, Cano A, Nappi RE, et al. Safety of fezolinetant for treatment of moderate to severe vasomotor symptoms due to menopause: pooled analysis of three randomized phase 3 studies. Adv Ther. 2025;42(2):1147\u201364.","journal-title":"Adv Ther"},{"issue":"8","key":"1737_CR5","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1007\/s12325-025-03242-3","volume":"42","author":"J Douxfils","year":"2025","unstructured":"Douxfils J, Boretti E, Beaudart C, Dogn\u00e9 JM. Letter to the editor regarding: safety of fezolinetant for treatment of moderate-to-severe vasomotor symptoms due to menopause: pooled analysis of three randomized phase 3 studies. Adv Ther. 2025;42(8):4089\u201391.","journal-title":"Adv Ther"},{"issue":"5","key":"1737_CR6","doi-asserted-by":"publisher","DOI":"10.1177\/03000605241246624","volume":"52","author":"Q Yu","year":"2024","unstructured":"Yu Q, Ming F, Ma J, et al. Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial. J Int Med Res. 2024;52(5):3000605241246624.","journal-title":"J Int Med Res"},{"key":"1737_CR7","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use. Veoza: public assessment report. EMA\/528775\/2023. Amsterdam: EMA. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/veoza-epar-public-assessment-report_en.pdf. Accessed 18 Aug 2026."},{"key":"1737_CR8","unstructured":"van der Vlugt T, Zopf R; Center for Drug Evaluation and Research. Clinical review, NDA 216578, fezolinetant tablets. Silver Spring (MD): US Food and Drug Administration. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/216578Orig1s000MedR.pdf. Accessed 18 Aug 2026."},{"issue":"1","key":"1737_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1152\/physrev.00031.2013","volume":"94","author":"MS Steinhoff","year":"2014","unstructured":"Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW. Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev. 2014;94(1):265\u2013301.","journal-title":"Physiol Rev"},{"issue":"6","key":"1737_CR10","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.3390\/jcm9061659","volume":"9","author":"M Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz M, Cove\u00f1as R. The neurokinin-1 receptor antagonist aprepitant, a new drug for the treatment of hematological malignancies: focus on acute myeloid leukemia. J Clin Med. 2020;9(6):1659.","journal-title":"J Clin Med"},{"issue":"7","key":"1737_CR11","first-page":"881","volume":"29","author":"R Cove\u00f1as","year":"2014","unstructured":"Cove\u00f1as R, Mu\u00f1oz M. Cancer progression and substance P. Histol Histopathol. 2014;29(7):881\u201390.","journal-title":"Histol Histopathol"},{"key":"1737_CR12","unstructured":"Astellas Pharma. European Union risk management plan for fezolinetant (VEOZA), version 4.3. CTD Module 1.8.2. Leiden: Astellas Pharma Europe B.V.; July 2026; published by the European Medicines Agency. published by the European Medicines Agency 21 August 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/veoza. Accessed 10 Sep 2026."},{"issue":"7","key":"1737_CR13","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s00726-014-1736-9","volume":"46","author":"M Mu\u00f1oz","year":"2014","unstructured":"Mu\u00f1oz M, Cove\u00f1as R. Involvement of substance P and the NK-1 receptor in human pathology. Amino Acids. 2014;46(7):1727\u201350. https:\/\/doi.org\/10.1007\/s00726-014-1736-9.","journal-title":"Amino Acids"},{"issue":"23","key":"1737_CR14","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/jnci\/88.23.1731","volume":"88","author":"JH Lee","year":"1996","unstructured":"Lee JH, Miele ME, Hicks DJ, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst. 1996;88(23):1731\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"1737_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00115","volume":"9","author":"V Ciaramella","year":"2018","unstructured":"Ciaramella V, Della Corte CM, Ciardiello F, Morgillo F. Kisspeptin and cancer: molecular interaction, biological functions, and future perspectives. Front Endocrinol (Lausanne). 2018;9:115.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"1737_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s10555-023-10090-6","volume":"42","author":"S Harihar","year":"2023","unstructured":"Harihar S, Welch DR. KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers? Cancer Metastasis Rev. 2023;42(1):183\u201396.","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"1737_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10585-020-10030-6","volume":"37","author":"S Harihar","year":"2020","unstructured":"Harihar S, Ray S, Narayanan S, Santhoshkumar A, Ly T, Welch DR. Role of the tumor microenvironment in regulating the anti-metastatic effect of KISS1. Clin Exp Metastasis. 2020;37(2):209\u201323.","journal-title":"Clin Exp Metastasis"},{"issue":"25","key":"1737_CR18","doi-asserted-by":"publisher","first-page":"40713","DOI":"10.18632\/oncotarget.17250","volume":"8","author":"T Wang","year":"2017","unstructured":"Wang T, Chen S, Wang S, et al. Targeting neurokinin-3 receptor: a novel anti-angiogenesis strategy for cancer treatment. Oncotarget. 2017;8(25):40713\u201323.","journal-title":"Oncotarget"},{"issue":"7","key":"1737_CR19","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1083\/jcb.200603152","volume":"174","author":"S Pal","year":"2006","unstructured":"Pal S, Wu J, Murray JK, et al. An antiangiogenic neurokinin-B\/thromboxane A2 regulatory axis. J Cell Biol. 2006;174(7):1047\u201358.","journal-title":"J Cell Biol"},{"issue":"5","key":"1737_CR20","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.fertnstert.2012.02.021","volume":"97","author":"A Cejudo Roman","year":"2012","unstructured":"Cejudo Roman A, Pinto FM, Dorta I, et al. Analysis of the expression of neurokinin B, kisspeptin, and their cognate receptors NK3R and KISS1R in the human female genital tract. Fertil Steril. 2012;97(5):1213\u20139.","journal-title":"Fertil Steril"},{"issue":"7","key":"1737_CR21","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/humrep\/det128","volume":"28","author":"H Ca\u00f1ete","year":"2013","unstructured":"Ca\u00f1ete H, Dorta I, Hern\u00e1ndez M, et al. Differentially regulated expression of neurokinin B (NKB)\/NK3 receptor system in uterine leiomyomata. Hum Reprod. 2013;28(7):1799\u2013808.","journal-title":"Hum Reprod"},{"key":"1737_CR22","unstructured":"Astellas Pharma Europe. Veoza 45 mg film-coated tablets: summary of product characteristics. PLGB 00166\/0437. Addlestone: Astellas; text revised 13 April 2026. https:\/\/www.medicines.org.uk\/emc\/product\/15361\/smpc. Accessed 18 Aug 2026."},{"key":"1737_CR23","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use. Lynkuet: public assessment report and summary of product characteristics. EMEA\/H\/C\/006298. Amsterdam: EMA. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynkuet. Accessed 18 Aug 2026."},{"key":"1737_CR24","unstructured":"Bayer plc. Lynkuet 60 mg soft capsules: summary of product characteristics. PL 00010\/0759. Reading: Bayer plc; text revised 3 August 2026. https:\/\/www.medicines.org.uk\/emc\/product\/101980\/smpc. Accessed 18 Aug 2026."},{"key":"1737_CR25","unstructured":"Bayer HealthCare Pharmaceuticals. Lynkuet (elinzanetant) capsules: US prescribing information. Whippany (NJ): Bayer. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219469s000lbl.pdf. Accessed 18 Aug 2026."},{"issue":"8","key":"1737_CR26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa2415566","volume":"393","author":"F Cardoso","year":"2025","unstructured":"Cardoso F, Parke S, Brennan DJ, et al. Elinzanetant for vasomotor symptoms caused by adjuvant endocrine therapy in breast cancer. N Engl J Med. 2025;393(8):753\u201363.","journal-title":"N Engl J Med"},{"issue":"9407","key":"1737_CR27","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","volume":"363","author":"L Holmberg","year":"2004","unstructured":"Holmberg L, Anderson H, HABITS Steering and Data Monitoring Committees. HABITS (hormonal replacement therapy after breast cancer: is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363(9407):453\u20135.","journal-title":"Lancet"},{"issue":"7","key":"1737_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/jnci\/djn058","volume":"100","author":"L Holmberg","year":"2008","unstructured":"Holmberg L, Iversen OE, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100(7):475\u201382.","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"1737_CR29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/jnci\/dji071","volume":"97","author":"E von Schoultz","year":"2005","unstructured":"von Schoultz E, Rutqvist LE, Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst. 2005;97(7):533\u20135.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1737_CR30","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2012.07.003","volume":"49","author":"M Fahl\u00e9n","year":"2013","unstructured":"Fahl\u00e9n M, Fornander T, Johansson H, et al. Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial. Eur J Cancer. 2013;49(1):52\u20139.","journal-title":"Eur J Cancer"},{"issue":"10","key":"1737_CR31","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1093\/jnci\/djac112","volume":"114","author":"S Cold","year":"2022","unstructured":"Cold S, Cold F, Jensen MB, Cronin-Fenton D, Christiansen P, Ejlertsen B. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2022;114(10):1347\u201354.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1737_CR32","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/jnci\/djac213","volume":"115","author":"RT Chlebowski","year":"2023","unstructured":"Chlebowski RT, Aragaki AK, Pan K. Systemic or vaginal hormone therapy after early breast cancer. J Natl Cancer Inst. 2023;115(2):222\u20133.","journal-title":"J Natl Cancer Inst"},{"key":"1737_CR33","unstructured":"Astellas Pharma US, Inc. Veozah (fezolinetant) tablets, for oral use: US prescribing information. NDA 216578. Northbrook (IL): Astellas; revised February 2026. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=cae9f798-24f9-4580-a4fc-e6c710cbda3c. Accessed 18 Aug 2026."},{"key":"1737_CR34","unstructured":"US Food and Drug Administration. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. Drug safety communication. Silver Spring (MD): FDA. 2024, updated 16 December 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-communications\/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due. Accessed 4 Sep 2026."},{"key":"1737_CR35","unstructured":"European Medicines Agency. Direct healthcare professional communication: Veoza (fezolinetant): risk of drug-induced liver injury and new recommendations on monitoring of liver function before and during treatment. Amsterdam: EMA. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/dhpc\/direct-healthcare-professional-communication-dhpc-veoza-fezolinetant-risk-drug-induced-liver-injury-new-recommendations-monitoring-liver-function-during-treatment_en.pdf. Accessed 10 Sep 2026."},{"key":"1737_CR36","unstructured":"Medicines and Healthcare products Regulatory Agency. Fezolinetant (Veoza): risk of liver injury; new recommendations to minimise risk. Drug safety update. London: MHRA. 2025. https:\/\/www.gov.uk\/drug-safety-update\/fezolinetantv-veoza-risk-of-liver-injury-new-recommendations-to-minimise-risk. Accessed 10 Sep 2026."},{"issue":"10","key":"1737_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.46234\/ccdcw2024.040","volume":"6","author":"K Sun","year":"2024","unstructured":"Sun K, Han B, Zeng H, Wang S, Li L, Chen R, et al. Incidence and mortality of cancers in female genital organs: China, 2022. China CDC Wkly. 2024;6(10):195\u2013202. https:\/\/doi.org\/10.46234\/ccdcw2024.040.","journal-title":"China CDC Wkly"},{"issue":"7917","key":"1737_CR38","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41586-022-04875-y","volume":"607","author":"Z Diamantopoulou","year":"2022","unstructured":"Diamantopoulou Z, Castro-Giner F, Schwab FD, et al. The metastatic spread of breast cancer accelerates during sleep. Nature. 2022;607(7917):156\u201362.","journal-title":"Nature"},{"key":"1737_CR39","unstructured":"Bayer AG. EU risk management plan for Lynkuet (elinzanetant), version 1.3. Date of report 18 August 2025."},{"issue":"6","key":"1737_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101076","volume":"4","author":"A Gompel","year":"2023","unstructured":"Gompel A, Stuenkel CA. Neurokinin 3 receptor antagonists for menopausal vasomotor symptoms, an appraisal. Cell Rep Med. 2023;4(6):101076.","journal-title":"Cell Rep Med"},{"issue":"3","key":"1737_CR41","doi-asserted-by":"publisher","first-page":"435","DOI":"10.21147\/j.issn.1000-9604.2019.03.05","volume":"31","author":"Y Xi","year":"2008","unstructured":"Xi Y, Wang W, Chen W, Han K, Qiao L, Chen W. Incidence and mortality of corpus uteri cancer in China, 2008-2012. Chin J Cancer Res. 2019;31(3):435\u201342.","journal-title":"Chin J Cancer Res"},{"key":"1737_CR42","unstructured":"Astellas Pharma AG. VEOZA (fezolinetant): public risk management plan summary, document version 2.0, based on European Union risk management plan version 4.2. Wallisellen: Astellas Pharma AG. 2026. https:\/\/www.swissmedic.ch\/dam\/swissmedic\/en\/dokumente\/marktueberwachung\/rmp\/fezolinetant_veoza_rmp-summary.pdf.download.pdf\/Fezolinetant_Veoza_Public_Risk_Management_Plan_Summary.pdf. Accessed 10 Sep 2026."},{"issue":"3","key":"1737_CR43","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/ng.306","volume":"41","author":"AK Topaloglu","year":"2009","unstructured":"Topaloglu AK, Reimann F, Guclu M, et al. TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for neurokinin B in the central control of reproduction. Nat Genet. 2009;41(3):354\u20138.","journal-title":"Nat Genet"},{"issue":"2","key":"1737_CR44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1210\/jc.2015-3621","volume":"101","author":"GL Fraser","year":"2016","unstructured":"Fraser GL, Ramael S, Hoveyda HR, Gheyle L, Combalbert J. The NK3 receptor antagonist ESN364 suppresses sex hormones in men and women. J Clin Endocrinol Metab. 2016;101(2):417\u201326.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1737_CR45","doi-asserted-by":"publisher","first-page":"e3519","DOI":"10.1210\/clinem\/dgab320","volume":"106","author":"GL Fraser","year":"2021","unstructured":"Fraser GL, Obermayer-Pietsch B, Laven J, et al. Randomized controlled trial of neurokinin 3 receptor antagonist fezolinetant for treatment of polycystic ovary syndrome. J Clin Endocrinol Metab. 2021;106(9):e3519\u201332.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01737-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01737-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01737-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:08:23Z","timestamp":1792022903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01737-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":45,"alternative-id":["1737"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01737-8","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Glen Clack is the founder and managing director of Ailse Oncology Ltd and holds consultancy and chief medical officer roles with several early-stage biotechnology companies in oncology and haematology; none of these relationships concerns fezolinetant, neurokinin-receptor antagonists or menopausal hormone therapy. Glen Clack and Jennifer Renwick are jointly engaged in non-commercial regulatory and formulary activity concerning transdermal oestradiol, including ongoing discussions with the Medicines and Healthcare products Regulatory Agency and a submission to the British National Formulary, and are jointly preparing a related manuscript, not yet submitted, arising from those discussions; they disclose these as professional interests relevant to the comparator considered in this commentary. The authors confirm that they have considered the journal\u2019s competing interests policy in full, including non-financial interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This article is a commentary on previously published clinical and pharmacovigilance data; it does not report any new study involving human participants or animals undertaken by the authors, and approval from an ethics committee was therefore not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; this commentary did not involve the recruitment of participants.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; this commentary does not contain data from any individual person.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analysed during the current study; all data discussed are available in the cited published sources.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; no custom code or software was generated for this commentary.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors used a large language model (Claude, Anthropic) during preparation of this article. Its use comprised assistance with drafting and reorganisation of text from the authors\u2019 own source material, preparation of tracked-changes and comparison versions of documents. All primary sources cited were obtained and read by the authors, all data and quantities were verified by the authors against those sources, and all interpretations, conclusions and recommendations are the authors\u2019 own. The authors take full responsibility for the content of the article and its supplementary material.","order":7,"name":"Ethics","label":"Use of Large Language Models","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GC conceived the commentary and drafted the manuscript. JR contributed to the critical revision of the manuscript including for important intellectual content. All authors read and approved the final version.","order":8,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}